BIOMARIN PHARMACEUTICAL INC - 10-Q Filing

BioMarin Pharmaceutical reports Q3 2026 results following Amicus Therapeutics acquisition and Alesta Therapeutics transaction.

SEC EDGAR ·

Tickers: $BMRN

Read the full article at SEC EDGAR

More Regulatory news